Experienced in Cardiac Ablation

Dr. Edward J. Kim

Radiology

Radiology Of Indiana P C

9998 Crosspoint Blvd, Suite 200,

Indianapolis, IN

Clinical Trials:Currently Recruiting for 1 Trial

Accepting New Patients

Experienced in Cardiac Ablation

Radiology Of Indiana P C

9998 Crosspoint Blvd, Suite 200,

Indianapolis, IN

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edward Kim is a Radiologist in Indianapolis, Indiana. Dr. Kim is rated as an Experienced provider by MediFind in Cardiac Ablation. His top areas of expertise are Liver Cancer, Lymphofollicular Hyperplasia, Vertigo, Liver Embolization, and Hepato-Pancreato-Biliary Surgery. Dr. Kim is currently accepting new patients.

His clinical research consists of co-authoring 218 peer reviewed articles and participating in 30 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Cardiac Ablation.

Specialties

Radiology

Licenses

Diagnostic Radiology in IN

Hospital Affiliations

Riverview Health

Community Hospital North

Franciscan Health Mooresville

Franciscan Health Indianapolis

Community Hospital East

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Anthem

CareSource

Locations

RADIOLOGY OF INDIANA P C
9998 Crosspoint Blvd, Suite 200, Indianapolis, IN 46256

Call: 317-579-2150

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Enrollment Status: Recruiting

Publish Date: October 10, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Avelumab, Peposertib

Study Phase: Phase 1/Phase 2

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2025

Intervention Type: Drug

Study Drug: Tisotumab Vedotin

Study Phase: Phase 2

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Biological, Procedure, Drug

Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab

Study Phase: Phase 1

An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1)

Enrollment Status: Terminated

Publish Date: September 08, 2025

Intervention Type: Biological

Study Drug: ET140203 Autologous T Cell Product

Study Phase: Phase 1

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Drug

Study Drug: Entrectinib

Study Phase: Phase 2

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Drug, Procedure

Study Drug: Olaparib

Study Phase: Phase 2

A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer

Enrollment Status: Active_not_recruiting

Publish Date: July 30, 2025

Intervention Type: Procedure, Drug

Study Drugs: Berzosertib, Irinotecan

Study Phase: Phase 2

A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

Enrollment Status: Active_not_recruiting

Publish Date: May 23, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Atezolizumab, Cobimetinib, Varlilumab

Study Phase: Phase 2

Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated With the Combination of Sorafenib Plus Nivolumab as First-Line of Systemic Therapy

Enrollment Status: Completed

Publish Date: February 11, 2025

Intervention Type: Biological, Drug

Study Drugs: Nivolumab, Sorafenib

Study Phase: Phase 2

A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors

Enrollment Status: Completed

Publish Date: November 22, 2024

Intervention Type: Biological, Other, Drug

Study Drugs: Navitoclax, Sorafenib, Sorafenib Tosylate

Study Phase: Phase 1

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Enrollment Status: Completed

Publish Date: November 05, 2024

Intervention Type: Drug

Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX

Study Phase: Phase 3

A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)

Enrollment Status: Terminated

Publish Date: June 20, 2024

Intervention Type: Drug

Study Drugs: Canakinumab, Pembrolizumab

Study Phase: Phase 2

A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma

Enrollment Status: Completed

Publish Date: April 05, 2024

Intervention Type: Procedure, Drug

Study Drugs: Atezolizumab, Cobimetinib

Study Phase: Phase 2

S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: February 09, 2024

Intervention Type: Drug

Study Drugs: PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil

Study Phase: Phase 1/Phase 2

A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer

Enrollment Status: Terminated

Publish Date: October 17, 2023

Intervention Type: Drug

Study Drug: Savolitinib

Study Phase: Phase 2

Phase I/II Trial of BMS-986205 and Nivolumab as First or Second Line Therapy in Hepatocellular Carcinoma

Enrollment Status: Terminated

Publish Date: August 22, 2023

Intervention Type: Biological, Drug

Study Drugs: IDO1 Inhibitor BMS-986205, Nivolumab

Study Phase: Phase 1/Phase 2

A Pilot Study of Intratumoral SD-101 (Toll-Like Receptor 9 Agonist), Nivolumab, and Radiotherapy for Treatment of Chemotherapy-Refractory Metastatic Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: August 01, 2023

Intervention Type: Drug, Biological, Radiation

Study Drugs: Nivolumab, SD-101 TLR9 Agonist

Study Phase: Phase 1

Assessment of Response of Unresectable Hepatocellular Carcinoma to Combination Chemoembolization and Stereotactic Body Radiation Therapy

Enrollment Status: Completed

Publish Date: June 18, 2023

Intervention Type: Radiation, Drug

Study Drug: Trans-Arterial Chemoembolization

Study Phase: Phase 2

An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC)

Enrollment Status: Terminated

Publish Date: August 23, 2022

Intervention Type: Biological

Study Drug: ET140202 Autologous T Cell Product

Study Phase: Phase 1

Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Enrollment Status: Unknown

Publish Date: May 24, 2022

Intervention Type: Drug, Procedure, Radiation

Study Drugs: mFOLFIRINOX, FOLFOX

Study Phase: Phase 2

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)

Enrollment Status: Terminated

Publish Date: May 17, 2022

Intervention Type: Drug

Study Phase: Phase 1

Phase II Multicenter Randomized Two-arm Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Pretreated Adult Patients With EGFR Wild-type ALK Rearrangement Negative Advanced/Metastatic Non-small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: January 24, 2022

Intervention Type: Drug

Study Phase: Phase 2

Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma

Enrollment Status: Terminated

Publish Date: November 30, 2021

Intervention Type: Procedure, Device

Study Phase: Phase 3

A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations

Enrollment Status: Completed

Publish Date: February 09, 2021

Intervention Type: Drug, Other

Study Phase: Phase 2

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Enrollment Status: Completed

Publish Date: September 11, 2020

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Enrollment Status: Terminated

Publish Date: February 07, 2020

Intervention Type: Drug

Study Phase: Phase 1

View 29 Less Clinical Trials

218 Total Publications

Family Strengthening to Prevent Family Separation and Entrance into Residential Care Institutions in Sierra Leone: A Quasi-experimental Study.

Journal: Child & youth care forum

Published: August 07, 2025

View All 218 Publications

Similar Doctors

Experienced in Cardiac Ablation

Dr. Raja S. Ramaswamy

Radiology | Interventional Radiology

Experienced in Cardiac Ablation

Dr. Raja S. Ramaswamy

Radiology | Interventional Radiology

Radiology Of Indiana P C

9998 Crosspoint Blvd, Suite 200,

Indianapolis, IN

(0.1 miles away)

317-579-2150

Experience:

16+ years

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Raja Ramaswamy is a Radiologist and an Interventional Radiologist in Indianapolis, Indiana. Dr. Ramaswamy has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in Cardiac Ablation. His top areas of expertise are Ascites, SVC Obstruction, Endometrial Cancer, Thrombectomy, and Gastrostomy. Dr. Ramaswamy is currently accepting new patients.

Experienced in Cardiac Ablation

Dr. Jothiharan Mahenthiran

Cardiology | Radiology | Cardiac Electrophysiology

Experienced in Cardiac Ablation

Dr. Jothiharan Mahenthiran

Cardiology | Radiology | Cardiac Electrophysiology

Community Physicians Of Indiana Inc

8075 N Shadeland Ave, Suite 310,

Indianapolis, IN

(2.5 miles away)

317-621-8640

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Jothiharan Mahenthiran is a Cardiologist and a Radiologist in Indianapolis, Indiana. Dr. Mahenthiran is rated as an Advanced provider by MediFind in Cardiac Ablation. His top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Atrial Fibrillation, Angina, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Mahenthiran is currently accepting new patients.

VIEW MORE CARDIAC ABLATION DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition

ConditionClose